NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon | Biotech Hunter

Enrollment

162

Participants

Timeline

Start Date

September 8, 2015

Primary Completion Date

October 31, 2019

Study Completion Date

January 16, 2020

Conditions

Multiple Sclerosis

Interventions

DRUG

Interferon beta-1b (Betaferon, BAY86-5046)

Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect autoinjector.

DEVICE

Betaconnect Autoinjector

Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect autoinjector.

Trial Locations (1)

Wermsdorf